Fuzen Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
- Paid Up Capital ₹ 0.50 M
- Company Age 10 Year, 10 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 42.23%
- Profit Growth 81.45%
- Ebitda -18.49%
- Net Worth 52.59%
- Total Assets 0.87%
About Fuzen Pharmaceuticals
Fuzen Pharmaceuticals Private Limited (FPPL) is a Private Limited Indian Non-Government Company incorporated in India on 21 March 2014 and has a history of Ten years and ten months. Its registered office is in Indore, Madhya Pradesh, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.50 M, as per Ministry of Corporate Affairs (MCA) records.
Abhijeet Chouhan and Aditya Chouhan serve as directors at the Company.
Company Details
-
Location
Indore, Madhya Pradesh, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24233MP2014PTC032568
-
Company No.
032568
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
21 Mar 2014
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Gwalior
Industry
Who are the key members and board of directors at Fuzen Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Abhijeet Chouhan
|
Director | 21-Mar-2014 | Current |
|
Aditya Chouhan
|
Director | 27-Apr-2017 | Current |
Financial Performance of Fuzen Pharmaceuticals.
Fuzen Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 42.23% increase. The company also saw a substantial improvement in profitability, with a 81.45% increase in profit. The company's net worth Soared by an impressive increase of 52.59%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Fuzen Pharmaceuticals?
In 2022, Fuzen Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Loan Wired Fintech Private LimitedAbhijeet Chouhan is a mutual person
-
Growide Portfolio Management LimitedAbhijeet Chouhan is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Fuzen Pharmaceuticals?
Fuzen Pharmaceuticals has a workforce of 9 employees as of Mar 21, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Fuzen Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Fuzen Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
